SAINT PAUL, Minn., April 12 /PRNewswire/ -- Brennen Medical, Inc., a world leader in oat beta glucan technology, announces the sale of its GlucaTex(R) and GlucaMesh(R) product line used in the surgical repair of hernias, to Genzyme Corp. Genzyme will begin worldwide marketing of these beta glucan impregnated meshes for hernia repair.
Brennen’s use of oat beta glucan is having a profound impact on the Company’s objective of providing innovative and improved technologies to the medical and surgical health care arena. Research indicates this plant derived complex carbohydrate offers the human body distinct advantages during tissue repair. Favorable cellular interaction of beta glucan and the body’s host cells allow successful surgical repairs and earlier recovery periods for the patient.
Phillip Lawin, President of Brennen Medical commented, “I am pleased that hernia patients and their surgeons worldwide now have access to these products via Genzyme, a world leader in biotechnology and medical device distribution.”
He also adds that “this technology of impregnating surgical devices with beta glucan could revolutionize the implantability and host acceptance of numerous devices and applications and I am encouraged by the next generations of glucan coated implantables that we have in development.”
Oat beta glucan products currently offered by Brennen include: wound dressings, creams, gel and surgical meshes.
Terms of the sale are undisclosed.
About Brennen Medical
Brennen Medical, a privately owned company, headquartered in Saint Paul, Minnesota, develops, manufactures and distributes medical devices specifically designed to enhance tissue repair. Founded in 1993 Brennen introduced oat beta glucan to manage the severe burn injury. The success and knowledge achieved utilizing oat beta glucan for burn, wound and skin care led to the application of this technology on surgical meshes. Today, Brennen is a world leader in oat beta glucan technology and the company continues its commitment of enhancing tissue repair by the application of oat beta glucan on a variety of surgical implants.
About Genzyme
A world leading biotechnology company, Genzyme, headquartered in Cambridge, Massachusetts, is dedicated to making a major impact on the lives of people with serious diseases. Founded in 1981 Genzyme has grown to a diversified enterprise with annual revenues exceeding $2 billion and more than 8,000 employees in locations spanning the globe.
Contact Information: Brennen Medical, LLC
Phillip Lawin, President/CEO Phone: 651-429-7413
Brennen Medical, Inc.
CONTACT: Phillip Lawin, President-CEO, Brennen Medical, LLC,+1-651-429-7413
Web site: http://www.brennenmedical.com/
